Upload Image (Max 20MB per Image)
RegeneRx Biopharmaceuticals has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel, related to Thymosin beta 4 (Tβ4). The patents are set to expire 2024-2026, the ...
Tags: Thymosin beta 4, Tβ4, RegeneRx Biopharmaceuticals